Exelixis, Inc.

NASDAQ:EXEL

37.2 (USD) • At close March 12, 2025
Bedrijfsnaam Exelixis, Inc.
Symbool EXEL
Munteenheid USD
Prijs 37.2
Beurswaarde 10,411,573,200
Dividendpercentage 0%
52-weken bereik 20.14 - 40.02
Industrie Biotechnology
Sector Healthcare
CEO Dr. Michael M. Morrissey Ph.D.
Website https://www.exelixis.com

An error occurred while fetching data.

Over Exelixis, Inc.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment

Vergelijkbare Aandelen

Sotera Health Company logo

Sotera Health Company

SHC

11.28 USD

10x Genomics, Inc. logo

10x Genomics, Inc.

TXG

10.85 USD

ShockWave Medical, Inc. logo

ShockWave Medical, Inc.

SWAV

334.75 USD

R1 RCM Inc. logo

R1 RCM Inc.

RCM

14.31 USD

Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc.

SRPT

99.77 USD

Nutex Health, Inc. logo

Nutex Health, Inc.

NUTX

46.18 USD

Intra-Cellular Therapies, Inc. logo

Intra-Cellular Therapies, Inc.

ITCI

131.25 USD

Azenta, Inc. logo

Azenta, Inc.

AZTA

38.2 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)